Clinical trial
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
NCT02531516 is registered in ClinicalTrials.gov with Aragon Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 19, 2015
- Completion date
- December 29, 2028
- Enrollment
- 1,503 (actual)
- Sites
- 263
Conditions
As the registry lists them; a condition with its own page is linked.